JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zalutsky, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zalutsky, M. R.

Current Status of Therapy of Solid Tumors: Brain Tumor Therapy

Michael R. Zalutsky, PhD

Departments of Radiology and Biomedical Engineering, Duke University Medical Center, Durham, North Carolina



View larger version (18K):

[in a new window]
  		FIGURE 1. Kaplan-Meier plot of survival of GBM patients and of all patients after locoregional treatment with 131I-labeled murine 81C6 mAb. Median survival for patients with GBM and for all patients was 69 and 79 wk, respectively. (Reprinted with permission of (18).)

 


View larger version (179K):

[in a new window]
  		FIGURE 2. Coregistered MRI and 18F-FDG PET images after surgery and as a function of time after treatment with 131I-labeled murine 81C6 mAb. At 5 wk, cavity margins exhibited increased 18F-FDG uptake and enhancement on MRI. Biopsy samples obtained from this patient at 24 and 52 wk showed radiation necrosis and macrophage infiltration but no tumor involvement. (Reprinted with permission of (18).)

 


View larger version (116K):

[in a new window]
  		FIGURE 3. Axial MR image (gadolinium enhanced, T1 weighted) coregistered with isodose contours for a patient treated with 3,700 MBq of 131I-labeled murine 81C6. Volume of surgically created tumor resection cavity in this patient was 51.2 cm3. (Reprinted with permission of (22).)

 


View larger version (21K):

[in a new window]
  		FIGURE 4. Relationship between absorbed dose and initial dose rate in 16 patients on whom biopsies were performed after treatment. (Reprinted with permission of (21).)

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.